PE20091181A1 - Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene - Google Patents

Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene

Info

Publication number
PE20091181A1
PE20091181A1 PE2008002190A PE2008002190A PE20091181A1 PE 20091181 A1 PE20091181 A1 PE 20091181A1 PE 2008002190 A PE2008002190 A PE 2008002190A PE 2008002190 A PE2008002190 A PE 2008002190A PE 20091181 A1 PE20091181 A1 PE 20091181A1
Authority
PE
Peru
Prior art keywords
oxidoestra
methylen
propenyl
ona
alkyl
Prior art date
Application number
PE2008002190A
Other languages
English (en)
Inventor
Klar Ulrich
Joachim Kuhnke
Rolf Bohlmann
Jan Huebner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091181A1 publication Critical patent/PE20091181A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Abstract

SE REFIERE A DERIVADOS DE 15,16-METILEN-17-(1´-PROPENIL)-17-3´- OXIDOESTRA-4-EN-3-ONA DE FORMULA (I), DONDE Z ES O, DOS H, NOR´ Y NNHSO2R´; R' ES H, ALQUILO C1-C10, ARILO, ARALQUILO C7-C20; R4 ES H, HALOGENO; R6a Y R6b SON CADA UNO H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10 O FORMAN JUNTOS METILENO, 1,2-ETANDIILO; R7 ES H, ALQUILO C1-C10, CICLOALQUILO C3-C6, ENTRE OTROS; R18 ES H, ALQUILO C1-C3. SON COMPUESTOS PREFERIDOS: 17ALFA-(1´-PROPENIL)-15ALFA,16ALFA-METILEN-17ß-3´-OXIDOESTRA-4-EN-3-ONA; 7ALFA-METIL-15ALFA,16ALFA-METILEN-17ALFA-(1´-PROPENIL)-17ß-3´-OXIDOESTRA-4-EN-3-ONA; (E/Z)-3-(HIDROXIIMINO)-17ALFA-(1´-PROPENIL)-18-METIL-15ß,16ß-METILEN-17ß-3´-OXIDOESTRA-4,6-DIENO; ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO TIENE EFECTO GESTAGENICO, SIENDO DE UTILIDAD EN LA CONTRACEPCION Y TRANSTORNOS POSMENOPAUSICOS
PE2008002190A 2007-12-29 2008-12-29 Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene PE20091181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063496A DE102007063496A1 (de) 2007-12-29 2007-12-29 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20091181A1 true PE20091181A1 (es) 2009-09-03

Family

ID=40585540

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002190A PE20091181A1 (es) 2007-12-29 2008-12-29 Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene

Country Status (24)

Country Link
US (1) US8623850B2 (es)
EP (1) EP2238148B1 (es)
JP (1) JP5600070B2 (es)
KR (1) KR20100110348A (es)
CN (1) CN101918427B (es)
AR (1) AR069963A1 (es)
AU (1) AU2008342915A1 (es)
BR (1) BRPI0821667A2 (es)
CA (1) CA2710486A1 (es)
CL (1) CL2008003921A1 (es)
CO (1) CO6321233A2 (es)
CR (1) CR11544A (es)
DE (1) DE102007063496A1 (es)
DO (1) DOP2010000202A (es)
EA (1) EA201001011A1 (es)
EC (1) ECSP10010317A (es)
ES (1) ES2397970T3 (es)
IL (1) IL206383A0 (es)
PA (1) PA8809801A1 (es)
PE (1) PE20091181A1 (es)
TW (1) TW200938205A (es)
UY (1) UY31581A1 (es)
WO (1) WO2009083271A1 (es)
ZA (1) ZA201005398B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2605041B2 (ja) * 1987-05-30 1997-04-30 株式会社リコー 感熱記録材料
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
EP2238148A1 (de) 2010-10-13
AR069963A1 (es) 2010-03-03
WO2009083271A1 (de) 2009-07-09
JP2011507927A (ja) 2011-03-10
AU2008342915A1 (en) 2009-07-09
ECSP10010317A (es) 2010-08-31
DOP2010000202A (es) 2010-07-31
UY31581A1 (es) 2009-08-03
ES2397970T3 (es) 2013-03-12
JP5600070B2 (ja) 2014-10-01
US20110003779A1 (en) 2011-01-06
BRPI0821667A2 (pt) 2015-06-16
EP2238148B1 (de) 2012-10-24
CO6321233A2 (es) 2011-09-20
ZA201005398B (en) 2012-12-27
CL2008003921A1 (es) 2010-02-12
CN101918427A (zh) 2010-12-15
TW200938205A (en) 2009-09-16
CA2710486A1 (en) 2009-07-09
PA8809801A1 (es) 2009-07-23
IL206383A0 (en) 2010-12-30
US8623850B2 (en) 2014-01-07
CN101918427B (zh) 2013-07-31
DE102007063496A1 (de) 2009-07-02
EA201001011A1 (ru) 2011-02-28
KR20100110348A (ko) 2010-10-12
CR11544A (es) 2010-08-27

Similar Documents

Publication Publication Date Title
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
PE20081383A1 (es) Inhibidores benzoimidazolicos de trpv1
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
PE20091181A1 (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
PE20090822A1 (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
AR078770A1 (es) Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse

Legal Events

Date Code Title Description
FC Refusal